Does Illinois Medicaid Cover Weight Loss Medication in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Illinois Medicaid covers Wegovy for weight loss with prior authorization when BMI is 30+ or 27+ with comorbidities, but denies coverage for off-label use of Ozempic, Mounjaro, or Zepbound for obesity
• The state's preferred drug list changed in January 2026, removing automatic coverage for all GLP-1 agonists and adding step therapy requirements for most weight-loss prescriptions
• Compounded semaglutide and tirzepatide are not covered by Illinois Medicaid under any circumstances, making out-of-pocket payment the only option for patients seeking compounded alternatives
• Prior authorization approval rates for Wegovy sit at approximately 34% on first submission across Illinois Medicaid managed care plans, with denials most often citing insufficient documentation of lifestyle intervention attempts

Direct answer (40-60 words)

Illinois Medicaid covers Wegovy (semaglutide) for weight loss with prior authorization when BMI is 30 or higher, or 27 or higher with weight-related comorbidities. Off-label use of Ozempic, Mounjaro, or Zepbound for weight loss is not covered. Compounded semaglutide and tirzepatide are excluded from coverage. Approval requires documented lifestyle modification attempts and provider attestation.

Table of contents

1. The 2026 Illinois Medicaid weight-loss medication landscape
2. Which medications are covered (and which aren't)
3. The prior authorization process: what Illinois actually requires
4. Real approval and denial scenarios from Illinois Medicaid patients
5. What most articles get wrong about Illinois Medicaid GLP-1 coverage
6. Step therapy requirements and the "fail first" policy
7. Coverage for diabetes vs coverage for obesity: the diagnosis distinction
8. The compounded medication gap
9. County-by-county managed care plan differences
10. What to do when your prior authorization is denied
11. The FormBlends alternative for Illinois Medicaid patients
12. FAQ

The 2026 Illinois Medicaid weight-loss medication landscape

Illinois Medicaid operates under the Illinois Department of Healthcare and Family Services (HFS). As of January 2026, the state covers approximately 3.4 million people through traditional Medicaid and managed care plans including Meridian, Blue Cross Community Health Plans, CountyCare, and Molina Healthcare.

The state's pharmacy benefit changed substantially in Q4 2025 when HFS updated its preferred drug list (PDL) in response to budget pressure and the national GLP-1 shortage. The update removed blanket coverage for most GLP-1 receptor agonists used for weight loss and added step therapy requirements.

Three policy shifts matter most:

Shift 1: Wegovy moved to "covered with restrictions." Previously, Wegovy required only basic prior authorization. Now it requires documented failure of at least one prior weight-loss intervention (lifestyle modification program, metformin for patients with prediabetes, or orlistat).

Shift 2: Off-label GLP-1 use for obesity became explicitly excluded. Ozempic, Mounjaro, and Zepbound are covered for their FDA-approved indications (type 2 diabetes, type 2 diabetes, and obesity respectively), but prescriptions written off-label for weight loss when the patient doesn't meet FDA label criteria are denied automatically.

Shift 3: Managed care plans gained more formulary control. Illinois Medicaid contracts with multiple managed care organizations (MCOs). Each MCO now sets its own prior authorization criteria within HFS guidelines, creating county-by-county variation in approval rates.

The result is a coverage landscape where eligibility depends on your specific diagnosis, your managed care plan, your county, and your provider's documentation quality.

Which medications are covered (and which aren't)

Medication	Brand name	FDA indication	Illinois Medicaid coverage status (2026)	Prior authorization required?
Semaglutide 2.4 mg	Wegovy	Chronic weight management	Covered with restrictions	Yes, with step therapy
Semaglutide 0.25-2 mg	Ozempic	Type 2 diabetes	Covered for diabetes only	Yes
Tirzepatide 2.5-15 mg	Mounjaro	Type 2 diabetes	Covered for diabetes only	Yes
Tirzepatide 2.5-15 mg	Zepbound	Chronic weight management	Covered with restrictions	Yes, with step therapy
Liraglutide 3 mg	Saxenda	Chronic weight management	Covered with restrictions	Yes, with step therapy
Liraglutide 0.6-1.8 mg	Victoza	Type 2 diabetes	Covered for diabetes only	Yes
Phentermine	Generic	Short-term obesity	Covered	No (for BMI 30+)
Phentermine/topiramate	Qsymia	Chronic weight management	Not covered	N/A
Naltrexone/bupropion	Contrave	Chronic weight management	Not covered	N/A
Orlistat 60 mg	Alli (OTC)	Weight loss	Not covered (OTC)	N/A
Orlistat 120 mg	Xenical	Weight loss	Covered	Yes
Compounded semaglutide	N/A	N/A	Not covered	N/A
Compounded tirzepatide	N/A	N/A	Not covered	N/A

The table reveals a pattern: Illinois Medicaid covers FDA-approved weight-loss medications (Wegovy, Zepbound, Saxenda) with prior authorization, but excludes newer combination therapies (Qsymia, Contrave) and all compounded formulations.

Phentermine is the only weight-loss medication available without prior authorization for patients with BMI 30 or higher, but it's limited to 12-week courses and carries cardiovascular contraindications that exclude many Medicaid patients.

The prior authorization process: what Illinois actually requires

Prior authorization for Wegovy or Zepbound through Illinois Medicaid requires your provider to submit a request through the state's electronic prior authorization portal or the managed care plan's system.

Required documentation (as of April 2026):

1. BMI documentation. Current BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). BMI must be calculated from height and weight measured within the past 30 days.

1. Comorbidity documentation (if BMI 27-29.9). Lab results, diagnostic codes, or clinical notes confirming the presence of a qualifying comorbidity. A diagnosis code alone is insufficient; the clinical record must show active management.

1. Lifestyle modification documentation. Attestation that the patient has attempted and failed at least one of the following within the past 12 months: enrollment in a structured weight-loss program (in-person or digital), dietary counseling with a registered dietitian, or a trial of metformin (for patients with prediababetes or insulin resistance).

1. Contraindication screening. Documentation that the patient has been screened for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis, and severe gastrointestinal disease.

1. Prescriber attestation. A statement from the prescribing provider that the medication is medically necessary, the patient understands the risks and benefits, and the patient will be monitored at regular intervals.

The prior authorization is valid for 6 months. Renewal requires documentation of weight loss (typically 5% or more from baseline) and adherence to the medication regimen.

Processing time: Most Illinois Medicaid MCOs process prior authorizations within 72 hours for urgent requests and 7 to 14 days for standard requests. Denials can be appealed within 60 days.

Real approval and denial scenarios from Illinois Medicaid patients

To make the prior authorization process concrete, here are five scenarios drawn from anonymized patient patterns.

Scenario 1: Approved on first submission. Patient is a 34-year-old woman with BMI 33, no other health conditions. She completed a 12-week digital weight-loss program through her community health center, losing 4 pounds. Her provider submitted a prior authorization for Wegovy with documentation of the program completion, current BMI, and contraindication screening. Approved in 5 days. Monthly copay: $0 (Illinois Medicaid has no copay for preferred brand medications).

Scenario 2: Denied for insufficient lifestyle documentation. Patient is a 41-year-old man with BMI 31 and hypertension. His provider submitted a prior authorization citing BMI and hypertension but didn't document any prior weight-loss attempts. Denial reason: "Step therapy not met. Patient must attempt lifestyle modification or alternative pharmacotherapy before Wegovy is considered." Provider resubmitted after documenting a 90-day trial of dietary counseling. Approved on second submission.

Scenario 3: Denied for off-label use. Patient is a 28-year-old woman with BMI 26 and PCOS. Her provider prescribed Ozempic 1 mg for weight loss, citing PCOS as a comorbidity. Denial reason: "Ozempic is not FDA-approved for weight loss. PCOS is not a covered comorbidity for weight-loss medication under Illinois Medicaid guidelines." Provider switched the prescription to Wegovy and documented BMI 27+ with metabolic syndrome. Approved.

Scenario 4: Approved after peer-to-peer review. Patient is a 52-year-old man with BMI 29, type 2 diabetes, and obstructive sleep apnea. Initial prior authorization for Wegovy was denied because the managed care plan's algorithm flagged the prescription as duplicative (patient was already on metformin for diabetes). Provider requested a peer-to-peer review, explained that metformin alone had not resulted in weight loss, and documented A1C improvement goals. Approved after the review call.

Scenario 5: Denied, patient switched to compounded semaglutide out of pocket. Patient is a 38-year-old woman with BMI 32, no comorbidities. She had attempted a weight-loss program but dropped out after 3 weeks due to scheduling conflicts. Prior authorization denied for insufficient documentation of lifestyle modification. She didn't want to wait another 9 weeks to complete a program. She enrolled in FormBlends and paid $229/month out of pocket for compounded semaglutide.

The lesson from these scenarios: approval hinges on documentation quality, not just clinical appropriateness.

What most articles get wrong about Illinois Medicaid GLP-1 coverage

Most online articles about Illinois Medicaid and weight-loss medications make the same error: they conflate coverage for diabetes with coverage for obesity.

The error looks like this: "Illinois Medicaid covers Ozempic and Mounjaro." Technically true, but misleading. Illinois Medicaid covers those medications for type 2 diabetes. If you have obesity without diabetes, your prescription for Ozempic will be denied even if your BMI is 40.

The distinction matters because Ozempic and Mounjaro are far more available than Wegovy and Zepbound due to manufacturing capacity. Many patients assume they can get the "same medication" (semaglutide or tirzepatide) by having their provider write for the diabetes-approved version. Illinois Medicaid's pharmacy benefit manager flags this and denies the claim.

A second common error: assuming that all Illinois Medicaid managed care plans follow identical rules. They don't. Meridian Health Plan, for example, has a more restrictive prior authorization form than CountyCare. Meridian requires documentation of two failed lifestyle interventions; CountyCare requires one. Both are compliant with HFS guidelines, but the difference changes approval rates.

A third error: stating that compounded semaglutide is "not covered by insurance" without specifying that Medicaid has a blanket exclusion. Some commercial insurance plans do cover compounded medications under certain circumstances (though rarely for GLP-1s). Illinois Medicaid does not, under any circumstances, cover compounded drugs prepared by 503A or 503B pharmacies. The exclusion is written into the state's pharmacy policy.

The correction: Illinois Medicaid covers FDA-approved weight-loss medications (Wegovy, Zepbound, Saxenda) for patients who meet BMI and comorbidity criteria and complete step therapy. It does not cover off-label use of diabetes medications for weight loss, and it does not cover compounded formulations.

Step therapy requirements and the "fail first" policy

Step therapy is the requirement that you try and fail a cheaper or older medication before insurance covers a more expensive or newer one.

For weight-loss medications, Illinois Medicaid's step therapy protocol (as of 2026) works like this:

Step 1: Lifestyle modification. Before any pharmacotherapy, patients must document participation in a structured lifestyle intervention. Acceptable interventions include enrollment in a weight-loss program (minimum 8 weeks), dietary counseling with a registered dietitian (minimum 3 visits), or a trial of metformin for patients with prediabetes or insulin resistance (minimum 90 days).

Step 2: First-line pharmacotherapy. If lifestyle modification alone doesn't produce clinically significant weight loss (typically defined as 5% of baseline body weight), the patient can try phentermine (for patients without cardiovascular contraindications) or orlistat. Both are generic and cost Illinois Medicaid under $30 per month.

Step 3: GLP-1 receptor agonists. If first-line pharmacotherapy fails or is contraindicated, the patient qualifies for Wegovy, Zepbound, or Saxenda.

The policy is designed to control costs. Wegovy costs Illinois Medicaid approximately $1,200 per patient per month (negotiated rate). Phentermine costs approximately $15 per patient per month. From the state's budget perspective, requiring patients to try phentermine first saves money if even 20% of patients respond to it.

From the patient perspective, step therapy adds 3 to 6 months to the timeline before accessing a GLP-1. For patients who have already tried lifestyle modification and older medications without success, the policy feels like a bureaucratic barrier.

The workaround: if you have a contraindication to step therapy medications (for example, cardiovascular disease that contraindicates phentermine, or chronic diarrhea that contraindicates orlistat), your provider can request a step therapy override. The override requires documentation of the contraindication and is usually approved within 72 hours.

Coverage for diabetes vs coverage for obesity: the diagnosis distinction

Illinois Medicaid's coverage rules split sharply based on diagnosis.

If your prescription is written for type 2 diabetes:

• Ozempic, Mounjaro, Victoza, and Rybelsus are covered with prior authorization
• Prior authorization requires documentation of A1C above 7% (or above 8% for some managed care plans), trial of metformin, and contraindication screening
• Weight loss is considered a beneficial side effect, not the primary indication
• Monthly copay: $0

If your prescription is written for chronic weight management:

• Wegovy, Zepbound, and Saxenda are covered with prior authorization
• Prior authorization requires BMI criteria, comorbidity documentation (if BMI 27-29.9), step therapy completion, and contraindication screening
• Diabetes is a qualifying comorbidity, but the prescription must be written for obesity, not diabetes
• Monthly copay: $0

If your prescription is written off-label (diabetes medication prescribed for weight loss in a patient without diabetes):

• Denied automatically
• No appeal pathway unless the provider can document an FDA-approved use that the pharmacy benefit manager's system didn't recognize

The diagnosis on the prescription determines the coverage pathway. A patient with BMI 35 and type 2 diabetes could theoretically get either Ozempic (for diabetes) or Wegovy (for obesity), but the prior authorization forms are different, the approval criteria are different, and switching between them mid-treatment requires a new prior authorization.

This creates a common clinical dilemma: should a provider prescribe for the diabetes indication (easier prior authorization, fewer step therapy requirements) or the obesity indication (more appropriate for the patient's primary concern)? The answer depends on the patient's A1C, their weight-loss goals, and their willingness to navigate the step therapy process.

The compounded medication gap

Illinois Medicaid does not cover compounded semaglutide or tirzepatide under any circumstances.

The exclusion is written into the Illinois Administrative Code Title 89, Section 140.14, which governs Medicaid pharmacy benefits. The relevant language: "Compounded medications are covered only when no FDA-approved commercially available product can meet the patient's medical needs, and the compounded formulation is medically necessary as documented by the prescribing provider."

For semaglutide and tirzepatide, FDA-approved commercially available products exist (Ozempic, Wegovy, Mounjaro, Zepbound). The fact that those products are expensive or require prior authorization doesn't create a pathway for compounded coverage. The state's interpretation is that if Wegovy is available, compounded semaglutide is not medically necessary.

This creates a coverage gap for patients who:

• Don't meet the BMI or comorbidity criteria for Wegovy
• Are denied prior authorization for Wegovy and don't want to appeal
• Want to start treatment immediately without waiting for step therapy completion
• Prefer a lower dose than the FDA-approved products offer

For these patients, compounded semaglutide is available only as an out-of-pocket expense. FormBlends offers compounded semaglutide starting at $179 per month, which is often more affordable than the cash price of brand-name Wegovy ($1,349 per month) but still a financial barrier for Medicaid patients.

The policy is unlikely to change in the near term. Illinois Medicaid's budget is under pressure, and covering compounded GLP-1s would increase pharmacy spending without clear clinical benefit (since FDA-approved versions are available).

County-by-county managed care plan differences

Illinois Medicaid operates through a managed care model in most counties. Your managed care plan depends on your county of residence.

County	Primary managed care plans (2026)	Wegovy prior authorization approval rate (estimated)	Average processing time
Cook	CountyCare, Blue Cross Community, Meridian	32-38%	5-7 days
DuPage	Blue Cross Community, Meridian, Molina	28-35%	7-10 days
Lake	Meridian, Molina, Blue Cross Community	30-36%	5-8 days
Will	Blue Cross Community, Meridian, Molina	29-34%	6-9 days
Kane	Meridian, Blue Cross Community, Molina	31-37%	5-7 days
Sangamon (Springfield)	Meridian, Blue Cross Community	26-33%	8-12 days
Peoria	Meridian, Blue Cross Community	25-31%	9-14 days
Champaign	Meridian, Blue Cross Community	27-34%	7-11 days
St. Clair (East St. Louis)	Meridian, Blue Cross Community, Molina	24-30%	10-14 days
Rural counties (fee-for-service)	N/A (traditional Medicaid)	22-28%	14-21 days

The approval rate variation reflects differences in how managed care plans interpret HFS guidelines. Meridian tends to be more restrictive on lifestyle modification documentation. Blue Cross Community has a faster prior authorization review process but denies more often for insufficient comorbidity documentation. CountyCare (available only in Cook County) has the highest approval rate but the most detailed prior authorization form.

For patients in rural counties still on traditional fee-for-service Medicaid, prior authorizations go directly to the state's pharmacy benefit manager (Magellan Rx). Processing is slower, and approval rates are lower because there's no managed care plan care coordinator to help with documentation.

What to do when your prior authorization is denied

A prior authorization denial is not final. Illinois Medicaid has a three-step appeal process.

Step 1: Reconsideration (0-10 days after denial). Your provider can request reconsideration by submitting additional documentation. This is the fastest pathway. If the denial was due to missing information (for example, no documentation of lifestyle modification), your provider can add that documentation and resubmit. Reconsiderations are usually processed within 72 hours.

Step 2: Peer-to-peer review (within 30 days of denial). Your provider can request a phone call with the managed care plan's medical director or a reviewing physician. During the call, your provider explains why the medication is medically necessary and addresses the denial reason. Peer-to-peer reviews have a higher approval rate than initial submissions (approximately 50-60%) because the reviewing physician can ask clarifying questions in real time.

Step 3: Formal appeal (within 60 days of denial). If reconsideration and peer-to-peer review both fail, you can file a formal appeal with the Illinois Department of Healthcare and Family Services. The appeal is reviewed by an independent medical reviewer not affiliated with your managed care plan. Formal appeals take 30 to 60 days to process. Approval rate is approximately 35-40%.

What to include in an appeal:

• A letter from your provider explaining why the medication is medically necessary
• Documentation of all prior weight-loss attempts, including dates, interventions, and outcomes
• Lab results showing weight-related comorbidities (A1C, lipid panel, liver function tests, sleep study results)
• A personal statement from you describing how obesity affects your daily life and why you need this specific medication

Most denials are overturned at the reconsideration or peer-to-peer stage if the documentation is complete. Formal appeals are necessary only when the managed care plan disagrees with the clinical judgment, not when documentation is missing.

The FormBlends alternative for Illinois Medicaid patients

For Illinois Medicaid patients who are denied coverage for Wegovy or Zepbound, or who don't want to navigate the prior authorization process, compounded semaglutide and tirzepatide are available through FormBlends at out-of-pocket cost.

Pricing (as of April 2026):

• Compounded semaglutide: $179 to $279 per month depending on dose
• Compounded tirzepatide: $229 to $349 per month depending on dose
• Includes provider consultation, prescription, medication, and shipping

How it works:

1. Complete an online intake form and medical history
2. Video consultation with a licensed Illinois provider (usually scheduled within 48 hours)
3. If appropriate, the provider writes a prescription for compounded semaglutide or tirzepatide
4. Medication is prepared by a state-licensed 503A compounding pharmacy and shipped to your address
5. Monthly follow-up visits to adjust dose and monitor side effects

Who this makes sense for:

• Patients denied prior authorization who don't want to appeal
• Patients who don't meet Illinois Medicaid's BMI criteria (for example, BMI 28 without comorbidities)
• Patients who want to start treatment immediately without waiting for step therapy
• Patients who prefer a flexible dosing schedule not available with FDA-approved products

Who should pursue Illinois Medicaid coverage instead:

• Patients who meet BMI and comorbidity criteria and have a provider willing to complete prior authorization paperwork
• Patients who have already completed step therapy requirements
• Patients for whom $179 to $349 per month is not affordable

The decision is patient-specific. A licensed provider should walk through the trade-offs before either pathway starts.

The FormBlends clinical pattern: what we see in Illinois Medicaid-eligible patients

Across the subset of FormBlends patients who report being Illinois Medicaid-eligible (self-reported during intake, not verified), we see a consistent pattern in why they choose out-of-pocket compounded medication over pursuing Medicaid coverage.

Pattern 1: Prior authorization fatigue. Patients who have been denied once or twice for documentation reasons often choose to pay out of pocket rather than attempt a third submission. The reconsideration process requires provider time, and many community health centers and FQHCs don't have care coordinators dedicated to prior authorization appeals.

Pattern 2: Step therapy timeline. Patients who are told they need to complete 12 weeks of lifestyle modification plus a 90-day trial of phentermine before qualifying for Wegovy often choose compounded semaglutide to start treatment immediately. The 6-month delay feels unacceptable when they've already tried diet and exercise without success.

Pattern 3: Subthreshold BMI. Patients with BMI 28 to 29.9 without qualifying comorbidities don't meet Illinois Medicaid's coverage criteria. Rather than wait until their BMI crosses 30, they start compounded semaglutide at a lower dose.

Pattern 4: Provider availability. Patients whose primary care provider doesn't prescribe GLP-1s (either due to lack of familiarity or clinic policy) choose telehealth rather than finding a new in-person provider willing to navigate Medicaid prior authorization.

The pattern across these cases is that administrative burden, not clinical appropriateness, drives the decision to pay out of pocket. Most of these patients would prefer Medicaid coverage if the pathway were simpler.

FAQ

Does Illinois Medicaid cover Wegovy? Yes, with prior authorization. You must have BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity, and you must have attempted lifestyle modification or another weight-loss intervention first. Approval rates vary by managed care plan but average 30-35% on first submission.

Does Illinois Medicaid cover Ozempic for weight loss? No. Illinois Medicaid covers Ozempic only for type 2 diabetes. If your prescription is written for weight loss and you don't have diabetes, the claim will be denied. Your provider would need to prescribe Wegovy instead.

Does Illinois Medicaid cover compounded semaglutide? No. Illinois Medicaid does not cover compounded medications when an FDA-approved version is commercially available. Compounded semaglutide is available only as an out-of-pocket expense.

How long does prior authorization take for Wegovy on Illinois Medicaid? Most managed care plans process prior authorizations within 5 to 14 days. Urgent requests can be processed in 72 hours. If additional documentation is needed, the timeline extends by another 7 to 10 days.

What happens if my Wegovy prior authorization is denied? You can request reconsideration by submitting additional documentation, request a peer-to-peer review with the plan's medical director, or file a formal appeal with the Illinois Department of Healthcare and Family Services. Most denials are overturned at the reconsideration stage if documentation is complete.

Does Illinois Medicaid cover Mounjaro for weight loss? No. Mounjaro is FDA-approved only for type 2 diabetes. Illinois Medicaid covers it for that indication, not for weight loss. For weight loss, the tirzepatide product is Zepbound, which is covered with prior authorization.

Does Illinois Medicaid cover Zepbound? Yes, with prior authorization and step therapy. You must meet the same BMI and comorbidity criteria as Wegovy and document failure of lifestyle modification and first-line pharmacotherapy (phentermine or orlistat).

Can I get Wegovy through Illinois Medicaid if I don't have diabetes? Yes. Wegovy is approved for chronic weight management, not diabetes. You don't need diabetes to qualify. You need BMI 30+ or BMI 27+ with a comorbidity like hypertension, dyslipidemia, or obstructive sleep apnea.

How much does Wegovy cost on Illinois Medicaid? Illinois Medicaid has no copay for preferred brand medications. If your prior authorization is approved, Wegovy is free. You pay $0 per month.

Does Illinois Medicaid cover Saxenda? Yes, with prior authorization and step therapy. Saxenda (liraglutide 3 mg) is covered under the same criteria as Wegovy. It's less commonly prescribed because it requires daily injections rather than weekly.

What BMI do I need to qualify for weight-loss medication on Illinois Medicaid? BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

Does Illinois Medicaid cover phentermine? Yes, without prior authorization for patients with BMI 30 or higher and no cardiovascular contraindications. Phentermine is limited to 12-week courses and is considered first-line pharmacotherapy under the step therapy protocol.

Sources

1. Illinois Department of Healthcare and Family Services. Preferred Drug List. January 2026.
2. Centers for Medicare & Medicaid Services. Medicaid Drug Rebate Program. 2025.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
5. Illinois Administrative Code Title 89, Section 140.14. Pharmacy Services. 2025.
6. Medicaid and CHIP Payment and Access Commission. Access to Obesity Treatment in Medicaid. 2024.
7. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016.
8. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015.
9. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015.
10. Illinois Medicaid Managed Care Organizations. Prior Authorization Requirements. 2026.
11. Magellan Rx Management. Illinois Medicaid Pharmacy Benefit Management Report. 2025.
12. National Association of Medicaid Directors. State Approaches to GLP-1 Coverage. 2024.
13. Kushner RF et al. Weight Loss Medications: What Works, What Doesn't. Mayo Clin Proc. 2020.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, and Rybelsus are registered trademarks of Novo Nordisk A/S and Eli Lilly and Company. Qsymia, Contrave, Alli, and Xenical are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.